Physician profile
Uma Choday
NPI 1114084613
$2,371.03
in general payments reported to CMS, 2019-2025
18 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $134 · 2021: $690 · 2022: $193 · 2023: $373 · 2024: $258 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $598.96 | 2022-2025 | Azstarys |
| Neuronetics, INC. | $522.02 | 2021 | |
| Ironshore Pharmaceuticals INC. | $189.04 | 2019-2024 | Jornay Pm |
| Neurocrine Biosciences, INC. | $174.99 | 2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $170.32 | 2020-2022 | |
| Neos Therapeutics, LP | $152.16 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $146.24 | 2021-2025 | Qelbree, Qelbree |
| Adlon Therapeutics L.P. | $80.95 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $62.72 | 2022-2025 | Spravato |
| Tris Pharma INC | $60.04 | 2024-2025 | Dyanavel Xr |
| Shire North American Group INC | $56.33 | 2019 | |
| Collegium Pharmaceutical, INC. | $41.45 | 2025 | Jornay Pm |
| Sage Therapeutics, LLC | $21.66 | 2022 | |
| Lundbeck LLC | $20.54 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.89 | 2025 | Caplyta |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $18.86 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.39 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $16.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uma Choday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.